Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Cytokeratin 20 CRISPR Activation Plasmid (h): sc-401153-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Cytokeratin 20 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Cytokeratin 20 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Cytokeratin 20 CRISPR Activation Plasmid (h) and Cytokeratin 20 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the KRT20 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Cytokeratin 20 Antibody (E-9): sc-271183
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cytokeratin 20 CRISPR Activation Plasmid (h) | sc-401153-ACT | 20 µg | $397.00 |
KRT20 encodes cytokeratin 20 (CK20), a type I intermediate filament protein that contributes to epithelial cytoskeletal architecture and tissue-specific differentiation programs. CK20 participates in keratin filament assembly and cross-talks with junctional complexes to support cell polarity, mechanical resilience, and barrier function in gastrointestinal and urothelial epithelia. Its expression is tightly regulated during epithelial maturation and is commonly used as a lineage marker reflecting changes in differentiation state and cytoskeletal remodeling. Altered KRT20 expression patterns are associated with epithelial dysregulation in cancer and inflammatory contexts, making it a useful readout for studies of tumor phenotype, invasion-associated cytoskeletal reorganization, and epithelial plasticity.
Cytokeratin 20 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous KRT20 expression without altering the underlying DNA sequence.
Cytokeratin 20 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the KRT20 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the KRT20 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Cytokeratin 20 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native KRT20 locus and enabling the study of Cytokeratin 20-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Cytokeratin 20 pathway restoration in tumor cells with silenced or reduced KRT20 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.